Asieris Pharmaceuticals (688176), a China-based global biopharma company, announced on Thursday that it has entered into a strategic partnership with UroViu Corporation, a US-based medical device company.

Under the partnership, Asieris Pharmaceuticals is to receive exclusive global rights to UroViu's patented technology of portable single-use cystoscope in the field of fluorescent imaging. Asieris Pharmaceuticals is to utilise this patented technology in combination with specific optical imaging agents to carry out research on the application of non-white light imaging technology in the diagnosis and postoperative monitoring of None-Muscle Invasive Bladder Cancer (NMBC) and will be responsible for the global commercialisation of the sterile single-use fluorescent Cystoscope.

Previously, Asieris Pharmaceuticals entered a cooperation agreement with UroViu in 2021 for the exclusive registration and commercialisation rights of its portable single-use flexible white light cystoscopy system in mainland China, Taiwan, Hong Kong and Macau.

Dr Susan Wang, SVP of Asieris Global Business Development & Strategic Partnership said, 'There is still a huge unmet need for more accessible and safer fluorescent cystoscopy in the diagnosis and surveillance of bladder cancer. We are thrilled to deepen and expand our collaboration with UroViu, which enabling us not only to broaden our technology portfolio, but also to expedite the implementation of Asieris' integrated strategy for bladder cancer diagnosis and treatment, aiming to provide more effective disease management options for bladder cancer patients.'